Abstract
Dyspnea and exercise limitation are the dominant symptoms of patients with chronic obstructive pulmonary disease (COPD) and progress relentlessly as the disease advances. Effective management of these disabling symptoms awaits a better understanding of their underlying physiology. Recent research has identified a number of physiological mechanisms that can be targeted for therapeutic manipulation. Thus, interventions that improve dynamic ventilatory mechanics during exercise or reduce ventilatory demand (relative to capacity) will consistently improve exertional symptoms and physical performance even in patients with severe COPD. In this review we will attempt to provide a physiological construct to explain how modern bronchodilator therapy effectively relieves dyspnea and improves exercise endurance in COPD. We will then discuss new advances in our understanding of how oxygen enrichment of the inspired air results in impressive improvements of exertional symptoms and exercise performance even in patients without significant activityinduced arterial oxygen desaturation. Finally, we will demonstrate how combining therapies that improve airflow dynamics with those that alter the central neural drive to breathe have additive and clinically meaningful benefits in patients with advanced COPD.
Keywords: COPD, spirometry, dynamic hyperinflation, bronchodilators, oxygen, heliox, respiratory mechanics, dyspnea, exercise capacity
Current Respiratory Medicine Reviews
Title: Pharmacological Treatment in Chronic Obstructive Pulmonary Disease
Volume: 4 Issue: 4
Author(s): Pierantonio Laveneziana, Dennis Jensen, Katherine Webb and Denis E. O'Donnell
Affiliation:
Keywords: COPD, spirometry, dynamic hyperinflation, bronchodilators, oxygen, heliox, respiratory mechanics, dyspnea, exercise capacity
Abstract: Dyspnea and exercise limitation are the dominant symptoms of patients with chronic obstructive pulmonary disease (COPD) and progress relentlessly as the disease advances. Effective management of these disabling symptoms awaits a better understanding of their underlying physiology. Recent research has identified a number of physiological mechanisms that can be targeted for therapeutic manipulation. Thus, interventions that improve dynamic ventilatory mechanics during exercise or reduce ventilatory demand (relative to capacity) will consistently improve exertional symptoms and physical performance even in patients with severe COPD. In this review we will attempt to provide a physiological construct to explain how modern bronchodilator therapy effectively relieves dyspnea and improves exercise endurance in COPD. We will then discuss new advances in our understanding of how oxygen enrichment of the inspired air results in impressive improvements of exertional symptoms and exercise performance even in patients without significant activityinduced arterial oxygen desaturation. Finally, we will demonstrate how combining therapies that improve airflow dynamics with those that alter the central neural drive to breathe have additive and clinically meaningful benefits in patients with advanced COPD.
Export Options
About this article
Cite this article as:
Laveneziana Pierantonio, Jensen Dennis, Webb Katherine and O'Donnell E. Denis, Pharmacological Treatment in Chronic Obstructive Pulmonary Disease, Current Respiratory Medicine Reviews 2008; 4 (4) . https://dx.doi.org/10.2174/157339808786263833
DOI https://dx.doi.org/10.2174/157339808786263833 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Atrial Fibrillation in Patients Undergoing Surgical Revascularization: An Update on Pharmacologic Prophylaxis
Cardiovascular & Hematological Agents in Medicinal Chemistry Effects of Anticancer Drugs in Reproductive Parameters of Juvenile Male Animals and Role of Protective Agents
Anti-Cancer Agents in Medicinal Chemistry Understanding the Role of Corona Virus based on Current Scientific Evidence - A Review with Emerging Importance in Pandemic
Recent Patents on Anti-Infective Drug Discovery Editorial (Thematic Issue: Targeting Inflammation in Cardiovascular Disease)
Medicinal Chemistry GRK2 at the Control Shaft of Cellular Metabolism
Current Pharmaceutical Design Neuroimmune Interactions and Psychologycal Stress Induced by Cohabitation with a Sick Partner: A Review
Current Pharmaceutical Design Platelets and Platelet Interaction with Progenitor Cells in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology The Heart Metabolism: Pathophysiological Aspects in Ischaemia and Heart Failure
Current Pharmaceutical Design How Effective are the Lipid Modifying Medicines at Preventing Coronary Heart Disease in Patients with Type 2 Diabetes?
Vascular Disease Prevention (Discontinued) Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression
Current Vascular Pharmacology The Effects of Olprinone, a Phosphodiesterase 3 Inhibitor, on Systemic and Cerebral Circulation
Current Vascular Pharmacology Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism Anaemia in Diabetes: An Emerging Complication of Microvascular Disease
Current Diabetes Reviews Impact of N-acetylcysteine and Etodolac Treatment on Systolic and Diastolic Function in a Rat Model of Myocardial Steatosis Induced by High-Fat-Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Glucose Tolerance: Hypothesis Testing on Malaysian Diabetic Community
Current Diabetes Reviews CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design Peripartum Cardiomyopathy: Moving Towards a More Central Role of Genetics
Current Cardiology Reviews Perception of Symptoms in Hypertensive Patients and the Relevance to the Application of Anti- Hypertensive Drug Therapy
Current Pharmaceutical Design Does Parkinson’s Disease and Type-2 Diabetes Mellitus Present Common Pathophysiological Mechanisms and Treatments?
CNS & Neurological Disorders - Drug Targets Peroxisome Proliferator-Activated Receptor ?? (PPAR??) and Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders